Key statistics
On Friday, Takeda Pharmaceutical Co Ltd (TAK:NYQ) closed at 13.33, 6.00% above its 52-week low of 12.58, set on Jun 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.28 |
---|---|
High | 13.35 |
Low | 13.25 |
Bid | 13.10 |
Offer | 13.42 |
Previous close | 13.29 |
Average volume | 2.28m |
---|---|
Shares outstanding | 3.18bn |
Free float | 3.17bn |
P/E (TTM) | 22.65 |
Market cap | 42.18bn USD |
EPS (TTM) | 0.5886 USD |
Annual div (ADY) | 0.9586 USD |
---|---|
Annual div yield (ADY) | 4.38% |
Div ex-date | Mar 27 2024 |
Div pay-date | Jul 08 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
- Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
- Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
- Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
- Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
- Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
- Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
More ▼